期刊文献+

New insights into the pathogenesis of Peyronie’s disease:A narrative review

原文传递
导出
摘要 Peyronie’s disease(PD)is a benign,progressive fibrotic disorder characterized by scar or plaques within the tunica albuginea(TA)of the penis.This study provides new insights into the pathogenesis of PD based on data from different studies regarding the roles of cytokines,cell signaling pathways,biochemical mechanisms,genetic factors responsible for fibrogenesis.A growing body of literature has shown that PD is a chronically impaired,localized,wound healing process within the TA and the Smith space.It is caused by the influence of different pathological stimuli,most often the effects of mechanical stress during sexual intercourse in genetically sensitive individuals with unusual anatomical TA features,imbalanced matrix metalloproteinase/tissue inhibitor of metalloproteinase(MMP/TIMP),and suppressed antioxidant systems during chronic inflammation.Other intracellular signal cascades are activated during fibrosis along with low expression levels of their negative regulators and transforming growth factor-β1 signaling.The development of multikinase agents with minimal side effects that can block several signal cell pathways would significantly improve fibrosis in PD tissues by acting on common downstream mediators.
出处 《Chronic Diseases and Translational Medicine》 CSCD 2020年第3期165-181,共17页 慢性疾病与转化医学(英文版)
  • 相关文献

参考文献5

二级参考文献29

  • 1Hellstrom W J, Bivalacqua TJ. Peyronie's disease: etiology, medical, and surgical therapy. J Androl 2000; 21: 347-54.
  • 2Gholami SS, Gonzalez-Cadavid NF, Lin CS, Rajfer J, Lue TF. Peyronie's disease: a review. J Urol 2003; 169: 1234-41.
  • 3Hauck EW, Diemer T, Schmelz HU, Weidner W. A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol 2006; 49: 987-97.
  • 4Kadioglu A, Akman T, Sanli O, Gurkan L, Cakan Met al. Surgical treatment of Peyronie's disease: a critical analysis. Eur Urol 2006; 50: 235-48.
  • 5Gonzalez-Cadavid NF, Magee TR, Ferrini M, Qian A, Vernet D etal. Gene expression in Peyronie's disease. Int J Impot Res 2002; 14: 361-74.
  • 6EI-Sakka AI, Hassoba HM, Pillarisetty R J, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. d Urol 1997: 158: 1391-4.
  • 7Haag SM, Hauck EW, Szardening-Kirchner C, Diemer T, Cha ES etal. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol 2007; 51:255-61.
  • 8Piao S, Choi M J, Tumurbaatar M, Kim W J, Jin HR et al. Transforming growth factor (TGF)-β type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-β1 responses in fibroblasts derived from Peyronie's plaque. J Sex Med 2010; 7: 3385-95.
  • 9Ryu JK, Piao S, Shin HY, Choi M J, Zhang LW etal. IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease. J Sex Med 2009; 6: 1284-96.
  • 10Pang M, Zhuang S. Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther 2010; 335: 266-72.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部